A Genetic Mouse Model of Parkinson’s Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine

Molecular Neurobiology

Volumn 52, Issue 3, 2015, Pages 1152-1164

  Brehm, N ^a   Bez, F ^b   Carlsson, T ^a,c   Kern, B ^a   Gispert, S ^a   Auburger, G ^a   Cenci, M A ^b  

^a GOETHE UNIVERSITY   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alpha synuclein; Mouse model; Parkinson s disease; Synaptic plasticity

Indexed keywords

ALPHA SYNUCLEIN; APOMORPHINE; DUAL SPECIFICITY PHOSPHATASE 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEIN FOS; MITOGEN ACTIVATED PROTEIN KINASE; NERVE PROTEIN; PRION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTRIATAL PROJECTION; DOPAMINERGIC NERVE CELL; DUSP1 GENE; DUSP6 GENE; DYSTONIA; ENZYME PHOSPHORYLATION; FEMALE; FOS GENE; GENE INDUCTION; GENETIC MODEL; INVOLUNTARY MOVEMENT; MOUSE; MUTANT; NERVE PROJECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; STEREOTYPY; WILD TYPE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DYSKINESIAS; GENETICS; HUMAN; LOCOMOTION; METABOLISM; MISSENSE MUTATION; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; POINT MUTATION; POSTSYNAPTIC DENSITY; PRION; PROMOTER REGION; PROTEIN PROCESSING; SUBSTANTIA NIGRA; TRANSGENE; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; APOMORPHINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DYSKINESIAS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LOCOMOTION; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; PHOSPHORYLATION; POINT MUTATION; POST-SYNAPTIC DENSITY; PRIONS; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TRANSGENES;

EID: 84942828573     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8911-6     Document Type: Article

References (84)

1. Gasser T (2005) Genetics of Parkinson’s disease. Curr Opin Neurol 18(4):363–369
2. Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16(2):R183–R194. doi:10.1093/hmg/ddm159
3. Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a008888. doi:10.1101/cshperspect.a008888
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047
5. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841. doi:10.1126/science.1090278
6. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP, Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: the PDGene database. PLoS Genet 8(3):e1002548. doi:10.1371/journal.pgen.1002548
7. H. LF (1912) Paralysis agitans. 1. Pathologische Anatomie., vol Vol. 3. Handbuch der Neurologie. Springer-Verlag Berlin
8. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88(6):493–500
9. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840. doi:10.1038/42166
10. George JM, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15(2):361–372
11. Kurz A, Wohr M, Walter M, Bonin M, Auburger G, Gispert S, Schwarting RK (2010) Alpha-synuclein deficiency affects brain Foxp1 expression and ultrasonic vocalization. Neuroscience 166(3):785–795. doi:10.1016/j.neuroscience.2009.12.054
12. Grant LM, Richter F, Miller JE, White SA, Fox CM, Zhu C, Chesselet MF, Ciucci MR (2014) Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson’s disease. Behav Neurosci 128(2):110–121. doi:10.1037/a0035965
13. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25(47):10913–10921. doi:10.1523/JNEUROSCI.2922-05.2005
14. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329(5999):1663–1667. doi:10.1126/science.1195227
15. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66–79. doi:10.1016/j.neuron.2009.12.023
16. Scott D, Roy S (2012) alpha-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 32(30):10129–10135. doi:10.1523/JNEUROSCI.0535-12.2012
17. Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, Cragg SJ, Wade-Martins R (2008) Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27(4):947–957. doi:10.1111/j.1460-9568.2008.06055.x
18. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 101(41):14966–14971. doi:10.1073/pnas.0406283101
19. Mones RJ, Elizan TS, Siegel GJ (1971) Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry 34(6):668–673
20. Olanow CW, Koller WC (1998) An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. American Academy of Neurology. Neurology 50(3 Suppl 3):S1–S57
21. Cenci MA (2014) Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson’s disease. Biochem Soc Trans 42(2):600–604. doi:10.1042/bst20140006
22. Ghiglieri V, Bagetta V, Pendolino V, Picconi B, Calabresi P (2012) Corticostriatal plastic changes in experimental L-DOPA-induced dyskinesia. Parkinsons Dis 2012:358176. doi:10.1155/2012/358176
23. Brotchie J, Jenner P (2011) New approaches to therapy. Int Rev Neurobiol 98:123–150. doi:10.1016/b978-0-12-381328-2.00005-5
24. Fisone G, Bezard E (2011) Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol 98:95–122. doi:10.1016/b978-0-12-381328-2.00004-3
25. Murer MG, Moratalla R (2011) Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front Neuroanat 5:51. doi:10.3389/fnana.2011.00051
26. Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99(2):381–392. doi:10.1111/j.1471-4159.2006.04124.x
27. Cerasa A, Fasano A, Morgante F, Koch G, Quattrone A (2014) Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. Front Neurol 5:49. doi:10.3389/fneur.2014.00049
28. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30(5):236–243. doi:10.1016/j.tins.2007.03.005
29. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57(1):17–26. doi:10.1002/ana.20296
30. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66(6):603–613. doi:10.1016/j.biopsych.2009.04.025
31. Giorgi M, D’Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G (2008) Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28(5):941–950. doi:10.1111/j.1460-9568.2008.06387.x
32. Pavon N, Martin AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59(1):64–74. doi:10.1016/j.biopsych.2005.05.044
33. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62(7):800–810. doi:10.1016/j.biopsych.2006.11.032
34. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22(12):5042–5054
35. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 65(1):171–222. doi:10.1124/pr.111.005678
36. Pinna A, Bonaventura J, Farre D, Sanchez M, Simola N, Mallol J, Lluis C, Costa G, Baqi Y, Muller CE, Cortes A, McCormick P, Canela EI, Martinez-Pinilla E, Lanciego JL, Casado V, Armentero MT, Franco R (2014) L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol 253:180–191. doi:10.1016/j.expneurol.2013.12.021
37. Nishijima H, Suzuki S, Kon T, Funamizu Y, Ueno T, Haga R, Suzuki C, Arai A, Kimura T, Meguro R, Miki Y, Yamada J, Migita K, Ichinohe N, Ueno S, Baba M, Tomiyama M (2014) Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model. Mov Disord 29(3):336–343. doi:10.1002/mds.25826
38. Suarez LM, Solis O, Carames JM, Taravini IR, Solis JM, Murer MG, Moratalla R (2014) L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 75(9):711–722. doi:10.1016/j.biopsych.2013.05.006
39. Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209–233. doi:10.1016/s0079-6123(10)83011-0
40. Sgambato-Faure V, Buggia V, Gilbert F, Levesque D, Benabid AL, Berger F (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64(11):936–947
41. Yamada H, Kuroki T, Nakahara T, Hashimoto K, Tsutsumi T, Hirano M, Maeda H (2007) The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens. Brain Res 1131(1):88–96. doi:10.1016/j.brainres.2006.11.011
42. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Herve D, Greengard P, Fisone G (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27(26):6995–7005. doi:10.1523/jneurosci.0852-07.2007
43. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV (2005) L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis 18(2):323–335. doi:10.1016/j.nbd.2004.10.005
44. Fasano S, Bezard E, D’Antoni A, Francardo V, Indrigo M, Qin L, Dovero S, Cerovic M, Cenci MA, Brambilla R (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 107(50):21824–21829. doi:10.1073/pnas.1012071107
45. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease. J Neurochem 101(2):483–497. doi:10.1111/j.1471-4159.2007.04456.x
46. Cenci MA (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. Amino Acids 23(1–3):105–109. doi:10.1007/s00726-001-0116-4
47. Ulusoy A, Sahin G, Kirik D (2010) Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci U S A 107(29):13159–13164. doi:10.1073/pnas.1003432107
48. Angot E, Brundin P (2009) Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S143–S147. doi:10.1016/S1353-8020(09)70802-8
49. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, Edwards RH (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 286(23):20710–20726. doi:10.1074/jbc.M110.213538
50. Taschenberger G, Garrido M, Tereshchenko Y, Bahr M, Zweckstetter M, Kugler S (2012) Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol 123(5):671–683. doi:10.1007/s00401-011-0926-8
51. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger G, Nussbaum RL (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24(2):419–429
52. Platt NJ, Gispert S, Auburger G, Cragg SJ (2012) Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice. PLoS ONE 7(5):e36397. doi:10.1371/journal.pone.0036397
53. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, Garcia-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernandez-Ruiz J, Gerlach M, Wullner U, Luddens H, Calabresi P, Auburger G, Gispert S (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS ONE 5(7):e11464. doi:10.1371/journal.pone.0011464
54. Tozzi A, Costa C, Siliquini S, Tantucci M, Picconi B, Kurz A, Gispert S, Auburger G, Calabresi P (2012) Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol Aging 33(8):1792–1799. doi:10.1016/j.neurobiolaging.2011.05.002
55. Kurz A, May C, Schmidt O, Muller T, Stephan C, Meyer HE, Gispert S, Auburger G, Marcus K (2012) A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J Neural Transm 119(3):297–312. doi:10.1007/s00702-011-0717-3
56. Chourbaji S, Zacher C, Sanchis-Segura C, Spanagel R, Gass P (2005) Social and structural housing conditions influence the development of a depressive-like phenotype in the learned helplessness paradigm in male mice. Behav Brain Res 164(1):100–106. doi:10.1016/j.bbr.2005.06.003
57. Cenci MA, Campbell K, Wictorin K, Bjorklund A (1992) Striatal c-fos induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra in the rat. Eur J Neurosci 4(4):376–380
58. Cenci MA, Campbell K, Bjorklund A (1993) Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience 57(2):275–296
59. Cenci MA, Lee CS, Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10(8):2694–2706
60. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15(1):120–132
61. Lee CS, Cenci MA, Schulzer M, Bjorklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 123(Pt 7):1365–1379
62. Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10(2):165–186
63. Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neurobiol Dis 42(3):327–340. doi:10.1016/j.nbd.2011.01.024
64. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262
65. Owens DM, Keyse SM (2007) Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26(22):3203–3213. doi:10.1038/sj.onc.1210412
66. Heiman M, Heilbut A, Francardo V, Kulicke R, Fenster RJ, Kolaczyk ED, Mesirov JP, Surmeier DJ, Cenci MA, Greengard P (2014) Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A 111(12):4578–4583. doi:10.1073/pnas.1401819111
67. Graybiel AM, Moratalla R, Robertson HA (1990) Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci U S A 87(17):6912–6916
68. Young ST, Porrino LJ, Iadarola MJ (1991) Cocaine induces striatal c-fos-immunoreactive proteins via dopaminergic D1 receptors. Proc Natl Acad Sci U S A 88(4):1291–1295
69. Paul ML, Graybiel AM, David JC, Robertson HA (1992) D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson’s disease. J Neurosci 12(10):3729–3742
70. Paul ML, Currie RW, Robertson HA (1995) Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity. Neuroscience 66(2):347–359
71. Cenci MA, Bjorklund A (1993) Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal Fos expression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Neurosci 5(8):1062–1070
72. Konradi C, Cole RL, Heckers S, Hyman SE (1994) Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 14(9):5623–5634
73. Riley BE, Gardai SJ, Emig-Agius D, Bessarabova M, Ivliev AE, Schule B, Alexander J, Wallace W, Halliday GM, Langston JW, Braxton S, Yednock T, Shaler T, Johnston JA (2014) Systems-based analyses of brain regions functionally impacted in Parkinson’s disease reveals underlying causal mechanisms. PLoS ONE 9(8):e102909. doi:10.1371/journal.pone.0102909
74. Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5(3):173–183. doi:10.1038/nrn1346
75. Huang CY, Tan TH (2012) DUSPs, to MAP kinases and beyond. Cell Biosci 2(1):24. doi:10.1186/2045-3701-2-24
76. Wu JJ, Zhang L, Bennett AM (2005) The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol Cell Biol 25(11):4792–4803
77. Sun H, Charles CH, Lau LF, Tonks NK (1993) MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75(3):487–493
78. Caunt CJ, Keyse SM (2013) Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. Febs J 280(2):489–504. doi:10.1111/j.1742-4658.2012.08716.x
79. Collins LM, O’Keeffe GW, Long-Smith CM, Wyatt SL, Sullivan AM, Toulouse A, Nolan YM (2013) Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons. Neuromolec Med 15(2):435–446. doi:10.1007/s12017-013-8230-5
80. Hoepken HH, Gispert S, Azizov M, Klinkenberg M, Ricciardi F, Kurz A, Morales-Gordo B, Bonin M, Riess O, Gasser T, Kogel D, Steinmetz H, Auburger G (2008) Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 212(2):307–313. doi:10.1016/j.expneurol.2008.04.004
81. Gass P, Eckhardt A, Schroder H, Bravo R, Herdegen T (1996) Transient expression of the mitogen-activated protein kinase phosphatase MKP-1 (3CH134/ERP1) in the rat brain after limbic epilepsy. Brain Res Mol Brain Res 41(1–2):74–80
82. Reffas S, Schlegel W (2000) Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochem J 352(Pt 3):701–708
83. Muda M, Boschert U, Dickinson R, Martinou JC, Martinou I, Camps M, Schlegel W, Arkinstall S (1996) MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J Biol Chem 271(8):4319–4326
84. Visanji NP (2014) Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia. Mov Disord 29(6):721. doi:10.1002/mds.25906